ArticleFrontiers in nutrition2026
Neuroprotective potential of the natural polyphenol Procyanidin B2 in spinal cord injury: a comprehensive study utilizing machine learning, network pharmacology, and
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The secondary injury cascade following spinal cord injury (SCI) drives severe inflammation and tissue destruction. Although the natural polyphenol Procyanidin B2 (PCB2) has well-documented neuroprotective properties, its specific therapeutic efficacy in SCI, as well as its precise therapeutic targets and immunomodulatory mechanisms, remain unclear. Methods: We applied an integrated Results: Network pharmacology initially yielded 59 shared targets, with functional enrichment pointing to PCB2's broad involvement in Toll-like receptor and p53 signaling, as well as tissue remodeling. This suggests its potential for multi-target anti-inflammatory and anti-apoptotic intervention. Machine learning algorithms then pinpointed Caspase-1 (CASP1) as the central regulatory node. Single-cell RNA sequencing showed that CASP1 expression surges specifically within macrophages and microglia following injury. Molecular docking supported a robust interaction (-7.2 kcal/mol) between PCB2 and the active pocket of CASP1. In our rat model, administering PCB2 notably hastened the return of bladder control and increased BBB locomotor scores. Histology confirmed that treated animals had smaller lesion volumes, better myelin integrity, and less inflammatory cell infiltration. At the molecular level, PCB2 significantly suppresses CASP1 expression, thereby blunting secondary damage. Conclusion: PCB2 demonstrates significant neuroprotective effects in SCI. Its mechanism primarily involves targeting
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.